Published in Cell on July 23, 2010
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature (2012) 4.53
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell (2011) 2.17
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer (2013) 2.17
Retinoids regulate stem cell differentiation. J Cell Physiol (2011) 1.91
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet (2015) 1.82
The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell (2013) 1.75
Principles and strategies for developing network models in cancer. Cell (2011) 1.65
Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov (2012) 1.53
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer (2015) 1.40
Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics (2011) 1.17
HOXC9 links cell-cycle exit and neuronal differentiation and is a prognostic marker in neuroblastoma. Cancer Res (2011) 1.10
Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia (2012) 1.09
New strategies in refractory and recurrent neuroblastoma: translational opportunities to impact patient outcome. Clin Cancer Res (2012) 1.04
Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer (2015) 1.01
Retinoic acid receptor β stimulates hepatic induction of fibroblast growth factor 21 to promote fatty acid oxidation and control whole-body energy homeostasis in mice. J Biol Chem (2013) 0.99
PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation. Biochem Biophys Res Commun (2012) 0.96
Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. Semin Cancer Biol (2011) 0.96
The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells. Oncogene (2012) 0.94
Understanding tumor heterogeneity as functional compartments--superorganisms revisited. J Transl Med (2011) 0.93
The receptor tyrosine kinase Alk controls neurofibromin functions in Drosophila growth and learning. PLoS Genet (2011) 0.92
Focal DNA copy number changes in neuroblastoma target MYCN regulated genes. PLoS One (2013) 0.88
Identifying the Ubiquitin Ligase complex that regulates the NF1 tumor suppressor and Ras. Cancer Discov (2013) 0.85
CFC1 is a cancer stemness-regulating factor in neuroblastoma. Oncotarget (2017) 0.84
SPRED proteins provide a NF-ty link to Ras suppression. Genes Dev (2012) 0.84
Genetic and functional studies implicate synaptic overgrowth and ring gland cAMP/PKA signaling defects in the Drosophila melanogaster neurofibromatosis-1 growth deficiency. PLoS Genet (2013) 0.83
Time-lapse imaging of neuroblastoma cells to determine cell fate upon gene knockdown. PLoS One (2012) 0.82
Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition. Int J Cancer (2012) 0.81
MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. Oncogene (2014) 0.81
Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One (2013) 0.81
Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma. Oncotarget (2015) 0.81
LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/β-catenin signalling in neuroblastoma. Oncotarget (2015) 0.79
PBX1 is a favorable prognostic biomarker as it modulates 13-cis retinoic acid-mediated differentiation in neuroblastoma. Clin Cancer Res (2014) 0.79
In vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGAP protein NF1. Cancer Res (2012) 0.79
Physiological and genomic consequences of adrenergic deficiency during embryonic/fetal development in mice: impact on retinoic acid metabolism. Physiol Genomics (2012) 0.79
Apoptotic cell death in neuroblastoma. Cells (2013) 0.79
The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation. Proc Natl Acad Sci U S A (2016) 0.79
The corepressor CTBP2 is a coactivator of retinoic acid receptor/retinoid X receptor in retinoic acid signaling. Mol Cell Biol (2013) 0.78
Classic Ras Proteins Promote Proliferation and Survival via Distinct Phosphoproteome Alterations in Neurofibromin-Null Malignant Peripheral Nerve Sheath Tumor Cells. J Neuropathol Exp Neurol (2015) 0.78
Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain. Elife (2016) 0.78
Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma. Br J Cancer (2011) 0.78
Retinoic acid inhibits the cytoproliferative response to weak 50‑Hz magnetic fields in neuroblastoma cells. Oncol Rep (2012) 0.78
Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens. Oncotarget (2016) 0.78
Effect of low doses of actinomycin D on neuroblastoma cell lines. Mol Cancer (2016) 0.76
ZNF423: Transcriptional modulation in development and cancer. Mol Cell Oncol (2014) 0.76
The "neuro" of neuroblastoma: Neuroblastoma as a neurodevelopmental disorder. Ann Neurol (2016) 0.76
A novel integrated gene coexpression analysis approach reveals a prognostic three-transcription-factor signature for glioma molecular subtypes. BMC Syst Biol (2016) 0.76
Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. BMC Cancer (2016) 0.76
Increased wild-type N-ras activation by neurofibromin down-regulation increases human neuroblastoma stem cell malignancy. Genes Cancer (2011) 0.76
Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance. Genome Med (2017) 0.75
A Drosophila screen identifies neurofibromatosis-1 genetic modifiers involved in systemic and synaptic growth. Rare Dis (2014) 0.75
In vivo and in vitro expression of the RASAL1 gene in human gastric adenocarcinoma and its clinicopathological significance. Oncol Lett (2011) 0.75
Zfp423 Regulates Sonic Hedgehog Signaling via Primary Cilium Function. PLoS Genet (2016) 0.75
The NF1 somatic mutational landscape in sporadic human cancers. Hum Genomics (2017) 0.75
Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B. Genes Cancer (2016) 0.75
Genome-wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastoma. Mol Carcinog (2016) 0.75
Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse. Oncotarget (2016) 0.75
TIAM1 variants improve clinical outcome in neuroblastoma. Oncotarget (2017) 0.75
Discovery of Stromal Regulatory Networks that Suppress Ras-Sensitized Epithelial Cell Proliferation. Dev Cell (2017) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
Neuroblastoma. Lancet (2007) 10.61
Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med (1999) 9.02
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med (1985) 7.79
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet (2001) 6.96
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol (2009) 5.12
Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92
The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell (1990) 4.84
Retinoic acid synthesis and signaling during early organogenesis. Cell (2008) 4.52
Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol (2006) 4.35
NF1 tumor suppressor gene function: narrowing the GAP. Cell (2001) 4.11
Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat (2000) 3.87
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell (2009) 2.93
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol (2006) 2.91
Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst (2006) 2.79
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell (2009) 2.73
The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell (2005) 2.73
Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med (1996) 2.66
Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Mol Cell (2003) 1.95
Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs). Nucl Recept Signal (2009) 1.80
Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat Neurosci (2002) 1.58
Inhibition of ALK signaling for cancer therapy. Clin Cancer Res (2009) 1.53
Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res (1983) 1.53
Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol (2008) 1.53
Neurofibromatosis type 1 gene mutations in neuroblastoma. Nat Genet (1993) 1.48
Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients. Genes Chromosomes Cancer (2006) 1.41
Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1. Hum Mutat (2004) 1.35
Too much of a good thing: retinoic acid as an endogenous regulator of neural differentiation and exogenous teratogen. Eur J Neurosci (2003) 1.32
The Phox2B homeobox gene is mutated in sporadic neuroblastomas. Oncogene (2004) 1.18
P38MAPK-dependent phosphorylation and degradation of SRC-3/AIB1 and RARalpha-mediated transcription. EMBO J (2006) 1.17
A coordinated phosphorylation cascade initiated by p38MAPK/MSK1 directs RARalpha to target promoters. EMBO J (2008) 1.16
Activation of the Ras-ERK pathway inhibits retinoic acid-induced stimulation of tissue transglutaminase expression in NIH3T3 cells. J Biol Chem (2003) 1.11
Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers. Cancer Res (1991) 1.08
Molecular diagnosis of neurofibromatosis type 1: 2 years experience. Fam Cancer (2007) 1.07
The Ras/Erk pathway induces primitive endoderm but prevents parietal endoderm differentiation of F9 embryonal carcinoma cells. J Biol Chem (1999) 1.00
Induction of RET proto-oncogene expression in neuroblastoma cells precedes neuronal differentiation and is not mediated by protein synthesis. Exp Cell Res (1995) 0.91
Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma. Am J Med Genet A (2003) 0.90
Homozygous deletion of the neurofibromatosis-1 gene in the tumor of a patient with neuroblastoma. Cancer Genet Cytogenet (1997) 0.88
Noonan syndrome and neuroblastoma. Arch Pediatr Adolesc Med (1995) 0.85
Promyelocytic leukemia-nuclear body formation is an early event leading to retinoic acid-induced differentiation of neuroblastoma cells. J Neurochem (2007) 0.83
The H-ras oncogene interferes with retinoic acid signaling and metabolism in NIH3T3 cells. Cancer Res (1995) 0.78
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
A genomic and functional inventory of deubiquitinating enzymes. Cell (2005) 9.36
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 7.88
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature (2003) 6.53
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell (2012) 6.07
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One (2008) 5.86
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol (2009) 5.12
Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol (2006) 4.67
Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics (2006) 4.57
Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol (2006) 4.54
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature (2012) 4.53
The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell (2005) 4.40
The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol (2005) 4.29
Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature (2008) 4.24
The human transcriptome map reveals extremes in gene density, intron length, GC content, and repeat pattern for domains of highly and weakly expressed genes. Genome Res (2003) 4.21
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (2012) 3.88
Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med (2008) 3.80
Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta (2008) 3.74
The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent '+4' cell markers. EMBO J (2012) 3.70
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res (2008) 3.70
Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23
Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci (2006) 3.20
Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells. Mol Cell Biol (2008) 3.02
Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature (2012) 2.96
ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell (2009) 2.93
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol (2006) 2.91
Retinal vascular caliber and the development of hypertension: a meta-analysis of individual participant data. J Hypertens (2014) 2.83
Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst (2006) 2.79
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell (2009) 2.73
The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell (2005) 2.73
Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA (2009) 2.72
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res (2009) 2.65
Sparse representation and Bayesian detection of genome copy number alterations from microarray data. Bioinformatics (2008) 2.65
Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet (2007) 2.55
Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. Pediatr Blood Cancer (2008) 2.50
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet (2009) 2.47
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol (2013) 2.25
Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am (2008) 2.24
Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am (2010) 2.21
Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem (2003) 2.14
Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain (2010) 2.11
Conservation of hotspots for recombination in low-copy repeats associated with the NF1 microdeletion. Nat Genet (2006) 2.11
Differentiated Troy+ chief cells act as reserve stem cells to generate all lineages of the stomach epithelium. Cell (2013) 2.10
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol (2010) 2.00
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet (2012) 1.96
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res (2006) 1.91
Domain-wide regulation of gene expression in the human genome. Genome Res (2007) 1.86
ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci U S A (2010) 1.85
Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84
The three-dimensional structure of human interphase chromosomes is related to the transcriptome map. Mol Cell Biol (2007) 1.82
Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy. Clin Infect Dis (2011) 1.82
Expression profiling predicts outcome in breast cancer. Breast Cancer Res (2002) 1.81
Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell (2011) 1.80
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res (2010) 1.79
Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest (2009) 1.78